Table S3 from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Fields of Study & Subjects
Pancreatic and Hepatic Oncology Research
Cancer Immunotherapy and Biomarkers
Immunotherapy and Immune Responses
Publication details
- Publication date
- 4 March 2026
- Language
- EN